昂利康(002940.SZ)：获得药品注册证书及药品补充申请批准通知书

Core Viewpoint - Company received drug registration certificates for Diclofenac Sodium Enteric-Coated Tablets and approval for the supplemental application of Sacubitril/Valsartan Tablets from the National Medical Products Administration [1] Group 1: Product Approvals - Diclofenac Sodium Enteric-Coated Tablets are indicated for inflammatory and degenerative rheumatic diseases, various non-articular soft tissue rheumatic pain, acute gout attacks, acute mild to moderate pain, and as an adjunct treatment for severe pain infections in the ear, nose, and throat [1] - Sacubitril/Valsartan Tablets are indicated for the treatment of chronic heart failure in adults with reduced ejection fraction and for primary hypertension [1] Group 2: Collaboration and Market Launch - The Sacubitril/Valsartan Tablets were developed in collaboration with Suzhou Pengxu Pharmaceutical Technology Co., Ltd. and Suzhou Jingyun Pharmaceutical Technology Co., Ltd. [1] - The 200mg formulation of Sacubitril/Valsartan Tablets is set to be approved for market launch in June 2024, and the company has received approval for an additional 100mg specification [1]